AIMMUNE THERAPEUTICS, INC. — Operating Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/79b432ff-4ffc-4273-8499-e8103fe4342e/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2019 | $-249.8M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-007384 |
| FY 2018 | $-215.3M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-005514 |
| FY 2017 | $-133.3M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-002466 |
| FY 2016 | $-81.5M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-004466 |
| FY 2015 | $-36.0M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-013998 |
| FY 2014 | $-11.1M | 2014-01-01 – 2014-12-31 | evidence 0001564590-16-013998 |
| FY 2013 | $-4.8M | 2013-01-01 – 2013-12-31 | evidence 0001564590-16-013998 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).